QIA56
MMP-9 ELISA Kit
Gelatinase B ELISA Kit, 92 kDa Gelatinase ELISA Kit, Matrix Metalloproteinase 9 ELISA Kit
Para preguntas en general por favor contacte a nuestro Servicio de Atención al Cliente:
Merck KGaA
Frankfurter Str. 250
64293 Darmstadt
Germany
Teléfono: +49 6151 72-0
Fax: +49 6151 72 2000
01 junio 2012
cargando
A non-isotopic, sandwich ELISA for the in vitro measurement of human MMP-9 in tissue culture supernatant, serum, or plasma.
| Información sobre producto | |||
|---|---|---|---|
| Format | 96-well plate | ||
| Form | 34 or 41 Tests | ||
| Detection method | Colorimetric | ||
| Species reactivity | human | ||
| Avoid freeze/thaw | Si | ||
| Specificity | Human pro-MMP-9 protein and MMP-9/TIMP-1 complex | ||
| Sensitivity | 0.1 ng/ml | ||
| Assay range | 0.625 - 20 ng/ml | ||
| Assay time | 3.5 h | ||
| Sample type | Tissue culture media, serum, plasma | ||
| Kit contains | 96-Well Coated Plate, MMP-9 Standard, Biotinylated Detector Antibody, 400X Streptavidin Peroxidase Conjugate, Diluent, Substrate, Assay Buffers, Stop Solution, Plate Sealer, and a user protocol. | ||
| Declaration | Not available for sale in Japan. | ||
| Almacenar y enviar información | |||
|---|---|---|---|
|
Advertencia de materiales peligrosos: Debido a la naturaleza de los materiales peligrosos de este envío, podrían aplicarse gastos de envío añadidos a su pedido. Ciertos tamaños pueden estar exentos de los gastos de envío añadidos a los materiales peligrosos. Consulte a su oficina local de ventas si desea más información relativa a esos gastos. |
|||
| Categoría de alamacenamiento | -20°C | ||
| Ship |
Dry Ice Only
Multiple Toxicity Values, refer to MSDS |
||
| Información de seguridad | |||
|---|---|---|---|
| Frase S |
S: 26-36/37/39-45 |
||
| Frase R |
R: 23/24/25-35-36-40-43 |
||
| Datos | |||
|---|---|---|---|
 The mean signal of each standard run in replicates of four in eight assays using two different lots of plates and two different lots of detector antibody.   The pooled coefficients of variation (according to the formula of Henry et. al., 1974) and between assay coefficients of variation are plotted against MMP-9 concentrations. The pooled data were collected from samples run eight times using two different lots of plates and two different lots of detector antibody in replicates of four on two separate occasions.  The study tested dilution-recovery of ten positive samples. The dilutions were run in the MMP-9 ELISA Kit and the "found" doses were plotted against the "expected" doses to determine linearity of dilution. The slope is not significantly different from one and the intercept is not significantly different from zero. These studies are consistent with the absence of cross-reacting and matrix effects such as pH, salts, and endogenous binders that interfere with the reagents used in the assay. <b>Note:</b> Ca = Cancer; NHS = Normal Human Sera; NHP = Normal Human Plasma; PMA = Phorbol 12-myristate 13-acetate; EGF = Epidermal Growth Factor; AR = Amphiregulin; Both = EGF and AR; A = 2 x 10<sup>6</sup> cells/ml; B = 1.0 x 10<sup>6</sup> cells/ml.  Levels of MMP-9 detected by the ELISA after immunoaffinity extraction of MMP-9 positive samples (PMA treated HT1080 and HL-60 cells) with a MMP-9 antibody that is not used in the ELISA, a TIMP-1 antibody, a TIMP-2 antibody and a TIMP-3 antibody.  APMA promotes the autocatalytic cleavage of the N-terminal propeptide of the latent 92-kDa enzyme to yield the active form of the enzyme. Analysis of the samples by zymography showed both cleavage of the proenzyme by APMA and a good correlation with the levels of the proenzyme determined with the MMP-9 ELISA. Several methods of MMP-9 induction were used to generate positive samples such as treatment with 50 ng/ml amphiregulin (AR), 50 ng/ml epidermal growth factor (EGF), 1 ng/ml transforming growth factor β (TGFβ) and 25 ng/ml phorbol 12-myristate 13-acetate (PMA). Normal human sera (NHS) containing moderate levels of MMP-9 were treated with APMA and analyzed. |
